Journal Logo

Articles by F. Fabbiano

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL: S876

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3:392-393, June 2019.

A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY: S1617

Chiaretti, S.; Bassan, R.; Vitale, A.; More

HemaSphere. 3:746, June 2019.